Cell surface co-signaling molecules in the control of innate and adaptive cancer immunity

Stasya Zarling, Lieping Chen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Recent advances in cancer immunotherapy have focused on manipulating co-signaling pathways to direct or fine-tune antitumor immune responses. This is based on the findings that co-signaling pathways are pivotal in positive and negative regulation of innate and adaptive immunity to antigens. Importantly, cancer cells as well as cells in cancer microenvironments often aberrantly express co-signaling molecules to evade tumor immunity. We will focus our discussion on two co-signaling pathways including CD137/CD137L and B7-H1/PD-1. The data from animal models and clinical trials indicate that monoclonal antibodies and recombinant proteins targeting these co-signaling molecules are able to stimulate antitumor immune responses or ablate immune suppression. Co-signaling molecules thus add a new modality for mechanism-based design of combined immunotherapy in the future.

Original languageEnglish (US)
Title of host publicationInnate Immune Regulation and Cancer Immunotherapy
PublisherSpringer New York
Pages251-266
Number of pages16
ISBN (Print)9781441999146, 9781441999139
DOIs
StatePublished - Jan 1 2012

Fingerprint

Adaptive Immunity
Immunotherapy
Neoplasms
Tumor Microenvironment
Protein Transport
Recombinant Proteins
Innate Immunity
Immunity
Animal Models
Monoclonal Antibodies
Clinical Trials
Antigens

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zarling, S., & Chen, L. (2012). Cell surface co-signaling molecules in the control of innate and adaptive cancer immunity. In Innate Immune Regulation and Cancer Immunotherapy (pp. 251-266). Springer New York. https://doi.org/10.1007/9781441999146_14

Cell surface co-signaling molecules in the control of innate and adaptive cancer immunity. / Zarling, Stasya; Chen, Lieping.

Innate Immune Regulation and Cancer Immunotherapy. Springer New York, 2012. p. 251-266.

Research output: Chapter in Book/Report/Conference proceedingChapter

Zarling, S & Chen, L 2012, Cell surface co-signaling molecules in the control of innate and adaptive cancer immunity. in Innate Immune Regulation and Cancer Immunotherapy. Springer New York, pp. 251-266. https://doi.org/10.1007/9781441999146_14
Zarling S, Chen L. Cell surface co-signaling molecules in the control of innate and adaptive cancer immunity. In Innate Immune Regulation and Cancer Immunotherapy. Springer New York. 2012. p. 251-266 https://doi.org/10.1007/9781441999146_14
Zarling, Stasya ; Chen, Lieping. / Cell surface co-signaling molecules in the control of innate and adaptive cancer immunity. Innate Immune Regulation and Cancer Immunotherapy. Springer New York, 2012. pp. 251-266
@inbook{6e7fc4d5c84b4e0d8fc81f4b4a169828,
title = "Cell surface co-signaling molecules in the control of innate and adaptive cancer immunity",
abstract = "Recent advances in cancer immunotherapy have focused on manipulating co-signaling pathways to direct or fine-tune antitumor immune responses. This is based on the findings that co-signaling pathways are pivotal in positive and negative regulation of innate and adaptive immunity to antigens. Importantly, cancer cells as well as cells in cancer microenvironments often aberrantly express co-signaling molecules to evade tumor immunity. We will focus our discussion on two co-signaling pathways including CD137/CD137L and B7-H1/PD-1. The data from animal models and clinical trials indicate that monoclonal antibodies and recombinant proteins targeting these co-signaling molecules are able to stimulate antitumor immune responses or ablate immune suppression. Co-signaling molecules thus add a new modality for mechanism-based design of combined immunotherapy in the future.",
author = "Stasya Zarling and Lieping Chen",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/9781441999146_14",
language = "English (US)",
isbn = "9781441999146",
pages = "251--266",
booktitle = "Innate Immune Regulation and Cancer Immunotherapy",
publisher = "Springer New York",

}

TY - CHAP

T1 - Cell surface co-signaling molecules in the control of innate and adaptive cancer immunity

AU - Zarling, Stasya

AU - Chen, Lieping

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Recent advances in cancer immunotherapy have focused on manipulating co-signaling pathways to direct or fine-tune antitumor immune responses. This is based on the findings that co-signaling pathways are pivotal in positive and negative regulation of innate and adaptive immunity to antigens. Importantly, cancer cells as well as cells in cancer microenvironments often aberrantly express co-signaling molecules to evade tumor immunity. We will focus our discussion on two co-signaling pathways including CD137/CD137L and B7-H1/PD-1. The data from animal models and clinical trials indicate that monoclonal antibodies and recombinant proteins targeting these co-signaling molecules are able to stimulate antitumor immune responses or ablate immune suppression. Co-signaling molecules thus add a new modality for mechanism-based design of combined immunotherapy in the future.

AB - Recent advances in cancer immunotherapy have focused on manipulating co-signaling pathways to direct or fine-tune antitumor immune responses. This is based on the findings that co-signaling pathways are pivotal in positive and negative regulation of innate and adaptive immunity to antigens. Importantly, cancer cells as well as cells in cancer microenvironments often aberrantly express co-signaling molecules to evade tumor immunity. We will focus our discussion on two co-signaling pathways including CD137/CD137L and B7-H1/PD-1. The data from animal models and clinical trials indicate that monoclonal antibodies and recombinant proteins targeting these co-signaling molecules are able to stimulate antitumor immune responses or ablate immune suppression. Co-signaling molecules thus add a new modality for mechanism-based design of combined immunotherapy in the future.

UR - http://www.scopus.com/inward/record.url?scp=84955365728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955365728&partnerID=8YFLogxK

U2 - 10.1007/9781441999146_14

DO - 10.1007/9781441999146_14

M3 - Chapter

SN - 9781441999146

SN - 9781441999139

SP - 251

EP - 266

BT - Innate Immune Regulation and Cancer Immunotherapy

PB - Springer New York

ER -